NEW YORK, Jan. 30, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased BT Group plc (NYSE:BT) securities between May 23, 2013 and January 23, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/bt-group-plc. There is no cost or obligation to you.
According to the complaint, BT Group made false and/or misleading statements and/or failed to disclose that: (i) BT Group’s Italian division had engaged in improper accounting practices; (ii) as a result, BT Group significantly overstated its earnings; (iii) the aforementioned would foreseeably cause BT Group to cut its revenue, earnings, and free cash flow forecasts; and (iv) as a result, BT Group’s public statements were materially false and misleading.
On October 27, 2016, the Company announced that it uncovered “inappropriate management behavior” at its Italian division and “identified certain historical accounting errors and reassessed certain areas of management judgment.” As a result, the Company announced that it had “written down the value of items on the balance sheet by £145 [million].” Then, on January 24, 2017, BT Group issued a news release “the adjustments identified have increased from the £145m announced in our half-year update to a total of around £530m.”
If you suffered a loss in BT Group you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/bt-group-plc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Italy Fines Apple €98.6 Million Over App Store Dominance
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 



